8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Mar 17, 2026·SEC
Harvard Bioscience, Inc.(HBIO)Earnings, Financials & Key Ratios
HBIO•NASDAQ
$6.63
Price updated Jul 7, 2026
AboutHarvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.Show more
- Revenue$87M-8.1%
- EBITDA$5M+589.5%
- Net Income-$57M-357.1%
- EPS (Diluted)-12.80-357.1%
- Gross Margin53.01%-8.9%
- EBITDA Margin6.14%+650.0%
- Operating Margin-0.73%+89.0%
- Net Margin-65.51%-397.1%
- ROE-147.13%-709.0%
HBIO Price & Volume
Harvard Bioscience, Inc. (HBIO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Strains Capital Structure Stability
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's precarious liquidity position
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and solvency pressure
Key Thesis Takeaways
- Harvard Bioscience faces a challenging outlook characterized by a sustained revenue decline, evidenced by a 4.7% year-over-year contraction in 2026Q1.
- The company's inability to achieve consistent operating leverage, coupled with a precarious debt-to-equity ratio of 4.39x, suggests significant execution risk regarding its fragmented brand portfolio.
- Investors should monitor the company's ability to stabilize cash flows, as the current liquidity buffer of $7.1M may be insufficient to support ongoing operations without further capital intervention.
Verdict Logic
evidenced by a cash balance of only $7.1M against a debt-to-equity ratio of 4.39x, suggests that the current business model lacks the necessary stability to support long-term shareholder value.
HBIO Growth Metrics
Harvard Bioscience, Inc. (HBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-2.25%
5 Years-3.25%
3 Years-8.6%
TTM-6.42%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM83.15%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM83.29%
Return on Capital
10 Years-1.19%
5 Years-2%
3 Years-2.05%
Last Year-0.97%
HBIO Recent Earnings
Harvard Bioscience, Inc. (HBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.33+46.8%
$0.62
Rev
$21M-2.1%
$21M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.01-102.9%
$0.35
Rev
$24M+2.7%
$23M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.01-300.0%
$0.01
Rev
$21M-10.9%
$23M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.01+60.0%
$0.03
Rev
$20M+7.6%
$19M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.33vs $0.62+46.8% | $21Mvs $21M-2.1% |
| Q2 2026 | Mar 12, 2026 | $0.01vs $0.35-102.9% | $24Mvs $23M+2.7% |
| Q4 2025 | Nov 6, 2025 | $0.01vs $0.01-300.0% | $21Mvs $23M-10.9% |
| Q3 2025 | Aug 11, 2025 | $0.01vs $0.03+60.0% | $20Mvs $19M+7.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Harvard Bioscience, Inc. (HBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.63 | $29.9M | -0.52 | -8.06% | -65.51% | -147.13% | — | |
| $55.08 | $1.1B | 18.86 | 6.77% | 16.03% | 27.71% | — | |
| $0.66 | $22.7M | -1.06 | — | — | -1034.04% | — | |
| $96.16 | $531.28M | 79.47 | 3.38% | 2.69% | 3.71% | — | |
| $7.89 | $901.06M | -6.41 | -9.23% | -3.46% | -3.41% | — | |
| $105.70 | $2.41B | 41.94 | 13.53% | 24.35% | 16.19% | — |
Compare HBIO vs Peers
Harvard Bioscience, Inc. (HBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HBIO SEC Filings & Documents
Harvard Bioscience, Inc. (HBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when HBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HBIO Frequently Asked Questions
Harvard Bioscience, Inc. (HBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Harvard Bioscience, Inc.'s revenue?
Harvard Bioscience, Inc. (HBIO) reported $85.5M in revenue for fiscal year 2025. This represents a 604% increase from $12.2M in 1998.
How fast is Harvard Bioscience, Inc. growing?
Harvard Bioscience, Inc. (HBIO) saw revenue decline by 8.1% over the past year.
Is HBIO profitable?
Harvard Bioscience, Inc. (HBIO) reported a net loss of $9.8M for fiscal year 2025.
Dividend & Returns
What is HBIO's return on equity?
Harvard Bioscience, Inc. (HBIO) has a return on equity (ROE) of -147.1%. Negative ROE indicates the company is unprofitable.
What is Harvard Bioscience, Inc.'s free cash flow?
Harvard Bioscience, Inc. (HBIO) generated $1.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.